Abstract: Cyclic di-GMP or cyclic dinucleotides thereof can be used to inhibit cancer cell proliferation or to increase cancer cell apoptosis in vitro as well as in vivo in a patient.

Abstract: The present invention provides compositions of saratin and methods of use thereof. One aspect of the invention is a method of prevention or mitigation of the development of adhesions, keloids and scars. The adhesions, keloids and scars can be due to surgery, such as plastic surgery or orthopedic surgery, or can be pre-existing scars. Another aspect of the invention is a method for treatment of flexor tendon injuries.

Abstract: The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.

Abstract: The invention is a cosmetic or dermatological cloth, comprising a water-insoluble nonwoven material, which is moistened with a cosmetic or dermatological impregnating solution comprising an oil-in-water emulsions having a viscosity of less than 2000 mPa·s and comprising one or more partially neutralized glyceride esters selected from the group consisting of monoglyceride and diglyceride esters of saturated fatty acids with citric acid and one or more fatty alcohols selected from the group consisting of branched and unbranched alkyl alcohols with 12 to 40 carbon atoms.

Abstract: Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a ?-opiate analgesic such as tramadol or an analogously acting molecular entity, and a capsaicin or an ester of capsaicin, and optionally in sustained release dosage form.

Abstract: A patch comprising a support having electrostatic properties is provided wherein a periphery of the support is coated with an adhesive material, and all or part of the non-adhesive surface of the support is covered with at least one biologically active substance in the form of particles that is adhered to the non-adhesive part of the support by electrostatic forces.

Abstract: The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.

Abstract: Resorbable lactide polymer thin membranes are disclosed. The thin membranes are constructed of polylactide resorbable polymers, which are engineered to be absorbed into the body relatively slowly over time in order to reduce potential negative side effects. The membranes are formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.300 mm. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be preshaped with relatively thick portions, and can be stored in sterile packages.

Abstract: The invention relates to the use of one or several synthetic or natural furan alkyls for preparing a drug preventing and/or treating obesity or overweight. The use of one or several synthetic or natural furan alkyls for cosmetically treating local excessive weight is also disclosed. Said furan alkyls preferably correspond to formula (I), wherein identical or different R1, R2, R3et R4 are independently of each other a hydrogen atom, a C1-C35alkyl radical, C1-C35 alcenyl radical or a C1-C35 alcynyl radical, preferably C10-C22, wherein said alkyl, alcenyl and alcynyl radicals are substitutable and R1, R2, R3 are preferably a hydrogen atom.

Abstract: Disclosed are compositions which modulate the interaction with nerve growth factor and precursors thereof with neurotrophic receptors. Also disclosed are methods of using the compositions of the invention, including methods of administration.

Abstract: A method for preparing an alkali metal salt comprising: (a) condensing a disilyloxydiene with an aldehyde in the presence of a titanium (IV) catalyst in an inert solvent to form a 5(S)-hydroxy-3-ketoester; (b) reducing the 5(S)-hydroxy-3-ketoester to a 3(R),5(S)-dihydroxyester in the presence of a di(lower alkyl)methoxyborane; and (c) hydrolyzing the 3(R),5(S)-dihydroxyester in the presence of an aqueous base to form an alkali metal salt.

Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.

Abstract: The present invention relates to cationic lipids, methods for preparing some and methods for effectively transporting anionic molecular substances into cell by using said cationic lipids. The present lipids are compatible to gene therapy due to their stability and highly transporting effects.

Abstract: Two hitherto unreported novel triterpene saponins were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of the triterpene saponin fraction have been elucidated to possess anti-inflammatory and analgesic activity. These two novel triterpene saponins and the triterpene saponin fraction may be used as pharmaceutical compositions in humans and mammals in need of such treatment.

Abstract: The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

Abstract: By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the recurrence of stroke in a patient who is beyond six months after the onset of stroke, is prevented.

Abstract: This invention provides compounds of Formula (I): wherein R1 and R2 are independent substituents or are fused to form spirocyclic rings; R3, RC, and R4 are as defined herein; and R5 is a substituted benzene ring or a substituted five or six membered heterocyclic ring having in its backbone 1, 2, or 3 heteroatoms including O, S, SO, SO2 or NR6; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor.

Abstract: The invention relates to the use of a pharmaceutically active derivative of N-phenylbenzamide of Formula (I) or of a pharmaceutically acceptable salt thereof, for preparing a medicament for the therapeutic treatment of Chronic Obstructive Pulmonary Disease (COPD). Compounds of Formula (I): wherein R1 is cyano, nitro, halogen, hydroxy, C1-C4 alkyl, methoxy or tetrazol-5-yl group, R2 is hydrogen, hydroxy or methoxy, R3 is a tetrazol-5-yl group or hydrogen, R4 and R5 are hydrogen if R3 is tetrazol-5-yl group, or R4 and R5 are independently selected from the group consisting of carboxy, methoxycarbonyl, ethoxycarbonyl and carbamoyl if R3 is hydrogen, and R6 is hydrogen or methyl.

Abstract: Formulations and uses of kahalalide F.

Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.